FDA Approves Bixlenvo: New Once-Daily HIV Tablet for Simplified Treatment
- Food and Drug Administration approval for Bixlenvo, a once-daily single tablet regimen designed to treat HIV in virologically suppressed adults, according to a corporate announcement from the company.
- The regulatory approval relies on findings from the Phase 3 ARTISTRY-1 and ARTISTRY-2 clinical trials, with data initially presented at the 33rd Conference on Retroviruses and Opportunistic Infections,...
- Bixlenvo is aimed at individuals who are currently doing well on single-tablet regimens, such as Biktarvy, but want to switch treatments, as well as those managing complex multi-tablet...
Gilead Sciences, Inc. has secured U.S. Food and Drug Administration approval for Bixlenvo, a once-daily single tablet regimen designed to treat HIV in virologically suppressed adults, according to a corporate announcement from the company. The newly approved medication combines bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a first-in-class capsid inhibitor that features a novel mechanism of action without cross-resistance to existing antiretrovirals, according to Gilead Sciences. The combination creates the smallest single tablet regimen and serves as the first and only such option tailored for patients on complex treatment regimens who cannot take currently available single-tablet therapies.
Clinical Trial Background and Patient Populations
The regulatory approval relies on findings from the Phase 3 ARTISTRY-1 and ARTISTRY-2 clinical trials, with data initially presented at the 33rd Conference on Retroviruses and Opportunistic Infections, according to company statements. Detailed results from ARTISTRY-1 were subsequently published in The Lancet, while ARTISTRY-2 findings appeared in Lancet HIV. According to Gilead Sciences, the ARTISTRY-1 study enrolled the oldest participant population to date in a Phase 3 registrational trial for HIV-1 treatment, posting a median participant age of 60 years. Patients in that trial took between two and 11 pills daily at baseline, with roughly 40 percent taking antiretroviral therapy more than once a day. Trial participants demonstrated extensive treatment experience, showing a median treatment duration of 28 years, a high prevalence of historical antiretroviral resistance at 67 percent with NRTI resistance, and an 81 percent proportion on complex regimens driven by resistance issues.
Treatment Simplification and Efficacy
Bixlenvo is aimed at individuals who are currently doing well on single-tablet regimens, such as Biktarvy, but want to switch treatments, as well as those managing complex multi-tablet schedules. In both registration trials, the new pill demonstrated comparable efficacy in maintaining virologic suppression at Week 48 and proved generally well tolerated, with no significant or new safety concerns identified, according to Gilead Sciences. The most frequently reported adverse reactions occurring in at least two percent of participants across the program were headache, nausea, and diarrhea.
Bixlenvo offers a new once-daily STR designed for the evolving needs of people with HIV.
Chloe Orkin, MD, lead primary investigator for ARTISTRY-1 and Clinical Professor of Infection and Inequities at Queen Mary University of London According to Dr. Orkin, the regulatory decision marks a significant development for individuals who cannot use guideline-recommended single-tablet regimens due to tolerability issues or pre-existing resistance. Phase 3 data also indicated that switching from complex multi-tablet regimens to Bixlenvo correlated with improvements in specific fasting lipid parameters and overall participant treatment satisfaction.
Bixlenvo continues Gilead’s long-term commitment to innovation in HIV.
Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences According to Daniel O’Day, the approval provides a novel option for patients seeking to simplify or switch their regimens, supporting the company’s broader pipeline of potential daily, weekly, and longer-acting treatment and prevention options.